CN Mobile Logo

Search form


MBCC 2011

MBCC 2011

Dr. Muss and his colleagues investigated the use of adjuvant chemotherapy in patients with lymph node-positive breast cancer to determine if older people got the same "bang for the buck" as younger people when given more aggressive modern regimens.

The growing popularity of personalized cancer care has increased interest in tools that can guide physicians to the best-tailored therapies for their patients.

Adding a third dimension to the therapeutic field and reversing treatment planning may provide safer and more effective dose delivery, according to recent studies discussed at the Miami Breast Cancer Conference.

Clinicians traditionally look to lymph node status when determining breast cancer prognosis. But do the nodes really deserve such attention?

Rapid advances in the prevention, diagnosis and treatment of breast cancer keep clinicians on their toes. And this last year offered no reprieve, according to Debu Tripathy, MD, who highlighted several recent shifts and refinements to practice in his talk at the Miami Breast Cancer Conference.

The combination of biomarkers and molecular pathology will aid oncologists in developing targeted treatments for breast cancer, according to Samuel Aparicio, MD, PhD, who will be delivering a presentation on recognizing breast cancer heterogeneity in targeted treatment at the Miami Breast Cancer Conference this week.

The early promise of treating triple-negative and basal-cell breast cancers with poly (ADP-ribose) polymerase (PARP) inhibitors is yet to be realized, according to Lisa A. Carey, MD, who will be delivering a presentation on treatment options for these patients at the Miami Breast Cancer Conference this week.


Subscribe to MBCC 2011 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.